Literature DB >> 20221587

Combined ascorbate and glutathione deficiency leads to decreased cytochrome b5 expression and impaired reduction of sulfamethoxazole hydroxylamine.

Sachin Bhusari1, Mahmoud Abouraya, Marcia L Padilla, Marie E Pinkerton, Nicholas J Drescher, James C Sacco, Lauren A Trepanier.   

Abstract

Sulfonamide antimicrobials such as sulfamethoxazole (SMX) have been associated with drug hypersensitivity reactions, particularly in patients with AIDS. A reactive oxidative metabolite, sulfamethoxazole-nitroso (SMX-NO), forms drug-tissue adducts that elicit a T-cell response. Antioxidants such as ascorbic acid (AA) and glutathione (GSH) reduce SMX-NO to the less reactive hydroxylamine metabolite (SMX-HA), which is further reduced to the non-immunogenic parent compound by cytochrome b (5) (b5) and its reductase (b5R). We hypothesized that deficiencies in AA and GSH would enhance drug-tissue adduct formation and immunogenicity toward SMX-NO and that these antioxidant deficiencies might also impair the activity of the b5/b5R pathway. We tested these hypotheses in guinea pigs fed either a normal or AA-restricted diet, followed by buthionine sulfoximine treatment (250 mg/kg SC daily, or vehicle); and SMX-NO (1 mg/kg IP 4 days per week, or vehicle), for 2 weeks. Guinea pigs did not show any biochemical or histopathologic evidence of SMX-NO-related toxicity. Combined AA and GSH deficiency in this model did not significantly increase tissue-drug adduct formation, or splenocyte proliferation in response to SMX-NO. However, combined antioxidant deficiency was associated with decreased mRNA and protein expression of cytochrome b (5), as well as significant decreases in SMX-HA reduction in SMX-NO-treated pigs. These results suggest that SMX-HA detoxification may be down-regulated in combined AA and GSH deficiency. This mechanism could contribute to the higher risk of SMX hypersensitivity in patients with AIDS with antioxidant depletion.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20221587      PMCID: PMC2910208          DOI: 10.1007/s00204-010-0530-z

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  38 in total

1.  Molecular mechanism of decreased glutathione content in human immunodeficiency virus type 1 Tat-transgenic mice.

Authors:  J Choi; R M Liu; R K Kundu; F Sangiorgi; W Wu; R Maxson; H J Forman
Journal:  J Biol Chem       Date:  2000-02-04       Impact factor: 5.157

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Plasma cysteine deficiency and decreased reduction of nitrososulfamethoxazole with HIV infection.

Authors:  D J Naisbitt; F J Vilar; A C Stalford; E G Wilkins; M Pirmohamed; B K Park
Journal:  AIDS Res Hum Retroviruses       Date:  2000-12-10       Impact factor: 2.205

4.  Association of drug-serum protein adducts and anti-drug antibodies in dogs with sulphonamide hypersensitivity: a naturally occurring model of idiosyncratic drug toxicity.

Authors:  S N Lavergne; R S Danhof; E M Volkman; L A Trepanier
Journal:  Clin Exp Allergy       Date:  2006-07       Impact factor: 5.018

5.  "Danger" conditions increase sulfamethoxazole-protein adduct formation in human antigen-presenting cells.

Authors:  S N Lavergne; H Wang; H E Callan; B K Park; D J Naisbitt
Journal:  J Pharmacol Exp Ther       Date:  2009-08-07       Impact factor: 4.030

6.  A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions.

Authors:  T P Reilly; L H Lash; M A Doll; D W Hein; P M Woster; C K Svensson
Journal:  J Invest Dermatol       Date:  2000-06       Impact factor: 8.551

7.  Status of selected nutrients and progression of human immunodeficiency virus type 1 infection.

Authors:  J D Bogden; F W Kemp; S Han; W Li; K Bruening; T Denny; J M Oleske; J Lloyd; H Baker; G Perez; P Kloser; J Skurnick; D B Louria
Journal:  Am J Clin Nutr       Date:  2000-09       Impact factor: 7.045

8.  Covalent binding of the nitroso metabolite of sulfamethoxazole is important in induction of drug-specific T-cell responses in vivo.

Authors:  Linling Cheng; Benjamin J Stewart; Qiang You; Dennis R Petersen; Joseph A Ware; Joseph R Piccotti; Thomas T Kawabata; Cynthia Ju
Journal:  Mol Pharmacol       Date:  2008-03-11       Impact factor: 4.436

9.  NADH cytochrome b5 reductase and cytochrome b5 catalyze the microsomal reduction of xenobiotic hydroxylamines and amidoximes in humans.

Authors:  Joseph R Kurian; Sunil U Bajad; Jackie L Miller; Nathaniel A Chin; Lauren A Trepanier
Journal:  J Pharmacol Exp Ther       Date:  2004-08-09       Impact factor: 4.030

10.  Sulfamethoxazole and its metabolite nitroso sulfamethoxazole stimulate dendritic cell costimulatory signaling.

Authors:  Joseph P Sanderson; Dean J Naisbitt; John Farrell; Charlotte A Ashby; M Jane Tucker; Michael J Rieder; Munir Pirmohamed; Stephen E Clarke; B Kevin Park
Journal:  J Immunol       Date:  2007-05-01       Impact factor: 5.422

View more
  3 in total

1.  Evaluation of sulfonamide detoxification pathways in haematologic malignancy patients prior to intermittent trimethoprim-sulfamethoxazole prophylaxis.

Authors:  Mahmoud Abouraya; James C Sacco; Brad S Kahl; Lauren A Trepanier
Journal:  Br J Clin Pharmacol       Date:  2011-04       Impact factor: 4.335

2.  Individual variability in the detoxification of carcinogenic arylhydroxylamines in human breast.

Authors:  Keelia Rhoads; James C Sacco; Nicholas Drescher; Amos Wong; Lauren A Trepanier
Journal:  Toxicol Sci       Date:  2011-03-29       Impact factor: 4.849

3.  Immunogenicity of trimethoprim/sulfamethoxazole in a macaque model of HIV infection.

Authors:  Yat Yee Wong; Eva G Rakasz; David J Gasper; Thomas C Friedrich; Lauren A Trepanier
Journal:  Toxicology       Date:  2016-08-23       Impact factor: 4.221

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.